Inactivation of human arylamine N-Acetyltransferase 1 by the hydroxylamine of p-Aminobenzoic acid

Biochemical Pharmacology

Volumn 60, Issue 12, 2000, Pages 1829-1836

  Butcher, Neville J ^a,b   Ilett, Kenneth F ^a,c   Minchin, Rodney F ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c Western Australian Centre for Pathology and Medical Research   (Australia)

Author keywords

Arylamine N acetyltransferase; Enzyme inactivation; Hydroxylamine; NAT1; PABA

Indexed keywords

4 AMINOBENZOIC ACID DERIVATIVE; ACETYL COENZYME A; ARYLAMINE ACETYLTRANSFERASE; FLUORENYLACETOHYDROXAMIC ACID; HYDROXYLAMINE; N HYDROXY 4 AMINOBENZOIC ACID; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER RISK; CONTROLLED STUDY; COVALENT BOND; CYTOSOL; DIALYSIS; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME KINETICS; HUMAN; HUMAN CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; WESTERN BLOTTING;

4-AMINOBENZOIC ACID; ARYLAMINE N-ACETYLTRANSFERASE; ENZYME INHIBITORS; HUMANS; HYDROXYLAMINE; ISOENZYMES; KINETICS; LEUKOCYTES, MONONUCLEAR;

EID: 0034672608     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00501-3     Document Type: Article

References (66)

1. Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver
2. Expression of monomorphic and polymorphic N-acetyltranferases in human colon
3. Acetylation by blood cells
4. Acetyltransferase in humans: Development and tissue distribution
5. Evidence for two closely related isozymes of arylamine N-acetyltransferase in human liver
6. Arylamine N-acetyltransferase activity in human cultured cell lines
7. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus
8. Nomenclature for N-acetyltransferases
9. Functional polymorphism of the human arylamine N-acetyltransferase type 1 gene caused by C(190)T and G(560)A mutations
10. Identification and characterization of variant alleles of human acetyltranferase NAT1 with defective function using p-aminosalicylate as an in vivo and in vitro probe
11. Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas
12. Genotyping human arylamine N-acetyltranferase type 1 (NAT1). The identification of two novel allelic variants
13. Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood
14. Metabolic activation of mutagenic heterocyclic aromatic amines from protein pyrolysates
15. N- and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferases expressed in COS-1 cells
16. Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus
17. Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases
18. Human N-acetylation of benzidine: Role of NAT1 and NAT2
19. Acetylation phenotype in colorectal carcinoma
20. Polyadenylation polymorphism in the N-acetyltransferase gene 1 (NAT1) increases risk of colorectal cancer
21. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer
22. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk
23. Association of the NAT1*10 genotype with increased chromosome aberrations and higher lung cancer risk in cigarette smokers
24. N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk
25. A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people
26. N-acetyltransferase 1 genetic polymorphism influences the risk of prostate cancer development
27. N-acetyltransferase 1 genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk
28. Hepatic microsomal metabolism of sulfamethoxazole to the hydroxylamine
29. N-oxidation of 4-chloroaniline by prostaglandin synthase
30. Oxidation of environmental carcinogens by prostaglandin H synthase
31. Peroxidase-dependent oxidation of sulfonamides by monocytes and neutrophils from humans and dogs
32. Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells
33. Metabolism of procainamide to a hydroxylamine by human neutrophils and mononuclear leukocytes
34. Synthesis and in vitro toxicity of the hydroxylamine metabolites of sulfonamides
35. The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions
36. Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism
37. Covalent binding of sulfamethoxazole reactive metabolites to human and rat liver subcellular fractions assessed by immunochemical detection
38. Metabolic activation and DNA adducts of aromatic amines and nitroaromatic hydrocarbons
39. Metabolic activation and detoxification of arylamines
40. N-Acetyltransferases, O-acetyltransferases and N,O-acetyltransferases: Enzymology and bioactivation
41. Suicide inactivation of hamster hepatic arylhydroxamic acid N,O-acyltransferase
42. Irreversible inhibition of rat hepatic transacetylase activity by N-arylhydroxamic acids
43. Analogues of N-hydroxy-4-acetylaminobiphenyl as substrates and inactivators of hamster hepatic acetyltransferases
44. Hepatic N-acetyltransferases: Selective inactivation in vivo by a carcinogenic N-arylhydroxamic acid
45. Characterization of hamster recombinant monomorphic and polymorphic N-acetyltransferases
46. Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells
47. Direct and simultaneous high-performance liquid chromatographic assay for the determination of p-aminobenzoic acid and its conjugates in human urine
48. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
49. Immunochemical detection of arylamine N-acetyltransferase in normal and neoplastic bladder
50. Arylhydroxamic acid bioactivation via acyl group transfer. Structural requirements for transacylating and electrophile-generating activity of N-(2-fluorenyl)hydroxamic acids and related compounds
51. Hepatic microsome N-glucuronidation and nucleic acid binding of N-hydroxy arylamines in relation to urinary bladder carcinogenesis
52. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms
53. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma
54. Aryl hydrocarbon hydroxylase and benzo[a]pyrene and (-)-trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene metabolism in human blood monocytes and lymphocytes
55. The arachidonic acid cascade: An immunologically based review
56. In vitro evaluation of a toxic metabolite of sulfadiazine
57. Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione
58. Site-directed mutagenesis of recombinant human arylamine N-acetyltransferase expressed in Escherichia coli: Evidence for direct involvement of Cys68 in the catalytic mechanism of polymorphic human NAT2
59. Structure-function studies of human arylamine N-acetyltransferases NAT1 and NAT2
60. On the active site of liver acetyl-CoA arylamine N-acetyltransferase from rapid acetylator rabbits (III/J)
61. In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV
62. Time-course of toxicity of reactive sulfonamide metabolites
63. Myocardial, hepatic, and renal damage resulting from para-aminobenzoic acid therapy
64. Dangers of orally administered para-aminobenzoic acid
65. Suppression of T-lymphocyte proliferation by sulphonamide hydroxylamines